ADC Therapeutics scores FDA approval for anti-CD19 blood cancer med Zynlonta esagonowsky Fri, 04/23/2021 – 16:06 More: ADC Therapeutics scores FDA approval for anti-CD19 blood cancer med Zynlonta Source: fierce
read moreRegeneron looks to inject another $330M into long-running manufacturing expansion plan: report fkansteiner Fri, 04/23/2021 – 11:38 More: Regeneron looks to inject another 0M into long-running manufacturing expansion plan: report Source: fierce
read moreLonza unveils plan for $218M small molecule manufacturing facility in Switzerland nhigginsdunn Fri, 04/23/2021 – 11:37 More: Lonza unveils plan for 8M small molecule manufacturing facility in Switzerland Source: fierce
read moreLatecomer GlaxoSmithKline ushers in 7th PD-1/L1 with FDA nod for Jemperli, treading on Keytruda’s ground aliu Fri, 04/23/2021 – 10:11 More: Latecomer GlaxoSmithKline ushers in 7th PD-1/L1 with FDA nod for Jemperli, treading on Keytruda's ground Source: fierce
read moreDrug type could offer a new approach to treating a number of cancers with PBRM1 mutations More: PARP inhibitors could exploit weaknesses in a range of cancers Source: News
read morePD-1 inhibitor approved to treat patients with specific biomarker More: FDA approves GSK’s Jemperli for dMMR endometrial cancer Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals